Fachbereich Veterinärmedizin



    Extended Spectrum Beta Lactamase (ESBL) Producing Escherichia coli at Broiler Farms in Jaffna District of Sri Lanka (2015)

    Mahalingam, Muralithas
    Chaisowwong, Warangkhana
    Arumugam, Murugananthan
    Baumann, Maximilian P.O. (WE 8)
    Rösler, Uwe (WE 10)
    The 4th Food Safety and Zoonoses Symposium for Asia Pacific
    Chiang Mai, Thailand, 03. – 05.08.2015
    The 4th food safety and zoonoses symposium for Asia Pacific | 3-5 August 2015 | Veterinary Public Health Centre for Asia Pacific — Veterinary Public Health Centre for Asia Pacific (VPHCAP), Faculty of Veterinary Medicine, Chiang Mai University (Hrsg.)
    — S. 60–63
    ISBN: 978-974-672-988-8
    URL (Volltext): http://www.vet.cmu.ac.th/symposium2015/download/ProceedingSym2015.pdf
    Institut für Lebensmittelsicherheit und -hygiene

    Königsweg 69
    14163 Berlin
    +49 30 838 62550

    Abstract / Zusammenfassung

    This preliminary study has conducted to detect the presence of Extended Spectrum Beta Lactamase producing Escherichia coli (ESBLEC) from commercial broiler farms in Jaffna district, Sri Lanka and to assess the risk factors regarding farm management from questionnaires. Pooled fecal and paired boot swabs samples were collected from 83 broiler farms. Both types of samples were individually processed for ESBL confirmation along with antibiotic susceptibility testing using disk diffusion methods (CLSI 2014). ESBL-EC were
    detected from 50.6% of samples from broiler farms. Isolation rates were 45.95% (34/74) from boots samples and 40.96% (34/83) from fecal samples. Antimicrobial resistance of fecal ESBL-EC isolates were Ciprofloxacin (91.2%), Nalidixic Acid (91.2%), Enrofloxacin (85.3%), Trimethoprim/Sulfamethoxazole (85.3%), Tetracycline (85.3%), Doxycline (52.9%), Amoxacillin/Clavulanic acid (17.6%), Chloramphenicol (14.7%). All isolates were susceptible to Imipenem and Nitrofurantoin. Furthermore, same ESBL-EC isolates had observed resistances to 91.2% of Quinolones, 85.3% of Folate pathways inhibitors and 79.4% of Fluoroquinolones.